Cedars-Sinai Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Cedars-Sinai Medical Center sits in the top decile of US sponsors by registered trial count (#106 of 15,742 sponsors by registered trial count).

339 total trials 70 currently recruiting 180 completed early-phase tilt top decile by trial count

Cedars-Sinai Medical Center: 339 sponsored US clinical trials, 70 recruiting.

Cedars-Sinai Medical Center sponsors 339 registered US clinical trials on ClinicalTrials.gov, 70 of them currently recruiting, and 180 completed. 42 of these trials are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bladder Cancer, with 6 trials.

Top-decile sponsor footprint

Cedars-Sinai Medical Center ranks in the top decile of sponsors by registered trial count (#106 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 35/100

180 of 230 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

339 total, page 4 of 7

TERMINATED NA

The Effect of Mindfulness/Meditation on Post-operative Pain and Opioid Consumption

NCT04855968

COMPLETED NA

The Effect of Cross-Education on Shoulder Arthroscopy

NCT04470570

COMPLETED

WARRIOR Ancillary Study for CCTA Analysis

NCT05035056

COMPLETED NA

Effect of Positive Attitudes on Behavior and Wellness

NCT04441632

COMPLETED Phase 2

Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)

NCT04348500

COMPLETED Phase 1

Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

NCT03751709

COMPLETED Phase 4

Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

NCT04225988

COMPLETED NA

SMS Education for Post-operative Pain

NCT04039191

COMPLETED

Wingspan One Year Vascular Imaging Events and Neurologic Outcomes

NCT04221984

COMPLETED Phase 4

A Study Comparing Fascia Iliaca Blockade vs Extracapsular Local Field Infiltration With Liposomal Bupivacaine

NCT04114058

TERMINATED NA

Virtual Reality in SOD

NCT03999333

COMPLETED

Intraoperative Fluorescence With Augmented Reality

NCT03888014

TERMINATED Phase 1

Detection of miRNAs in HPA Axis Function in Healthy Subjects

NCT04066647

COMPLETED

A Prospective Case Series Analysis of Initial Users of the Urovac Device

NCT03872518

COMPLETED Phase 3

Effect of Evolocumab on Coronary Atherosclerosis

NCT03689946

COMPLETED NA

Endoscopic Trigger Finger Release

NCT03883477

COMPLETED NA

The IBD&me Randomized Controlled Trial

NCT03695783

COMPLETED

Dynamic Web-Based Interventions to Improve Update of Preventive Health Recommendations in IBD

NCT05997537

COMPLETED

Tissue Expansion in Breast Reconstruction Without Drains

NCT03784859

TERMINATED NA

Virtual Reality After Breast Reconstruction Surgery

NCT03801616

COMPLETED NA

Ultrasound Guided Peripheral IV Insertion

NCT03841864

TERMINATED NA

Use of Platelet Rich Plasma After Arthroscopic Debridement for Triangular Fibrocartilage Complex Tears

NCT03805698

TERMINATED NA

Reactive vs. Proactive Pain Control in IBD

NCT03798405

TERMINATED Phase 2

Efficacy and Safety of SYN-010 in IBS-C

NCT03763175

COMPLETED

Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification

NCT03815110

COMPLETED Phase 4

Personalized Treatments for Depressive Symptoms in Patients With Advanced Heart Failure

NCT03688100

COMPLETED NA

Cut Your Blood Pressure 3

NCT03726710

COMPLETED Phase 4

Prospective Randomized Controlled Trial of an Enhanced Recovery Protocol for Anorectal Surgery

NCT03738904

COMPLETED Phase 4

Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)

NCT03723447

TERMINATED Phase 2

Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence

NCT03219372

COMPLETED Phase 2

Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance

NCT03679260

TERMINATED Early Phase 1

Maintenance Dosing of Vitamin D in Crohn's Disease

NCT03615378

TERMINATED Phase 2

Rifaximin on Visceral Hypersensitivity

NCT03462966

COMPLETED NA

The Impact of Community Exercise on Social Connectedness and Falls in Older Adults: Leveraging Exercise to Age in Place

NCT03624049

COMPLETED NA

Development and Validation of a Digital Pain-Reduction Kit for Musculoskeletal Injuries

NCT03187132

TERMINATED Phase 4

Antibiotics During Intrauterine Balloon Tamponade Placement

NCT03478163

COMPLETED Phase 2

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

NCT03418324

TERMINATED NA

Virtual Reality in Labor and Delivery for Reduction in Pain

NCT03437031

COMPLETED NA

Comparison of Two Electroencephalograms (EEG) Monitors in Patients Undergoing General Anesthesia

NCT02928172

TERMINATED NA

Comparison of 3 Direct Laryngoscopes for Tracheal Intubation in Patients Undergoing Lumbar Spine Surgery

NCT02955511

COMPLETED NA

Comparative Effectiveness Trial of Communication Strategies in the Management of Chronic Pain

NCT03301623

TERMINATED Early Phase 1

The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy

NCT02653833

COMPLETED Phase 1

ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

NCT03145298

COMPLETED NA

Analgesic Efficacy of Anterior Femoral, Genicular and Adductor Canal Nerve Block

NCT02548104

COMPLETED NA

High Resolution MRI Study for Prostate Cancer

NCT03292874

COMPLETED Phase 4

Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

NCT03194321

COMPLETED NA

Trial of Low Residue Diet Versus Clear Liquids Following Elective Colorectal Surgery

NCT03260426

TERMINATED Phase 1

Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function

NCT03166787

COMPLETED Phase 2

18-F Sodium Fluoride (18F-NaF) PET for the Assessment of Bioprosthetic Aortic Valve Durability and Outcomes

NCT03095313

COMPLETED Phase 2

Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs

NCT02941705

← Previous Page 4 of 7 Next →

What is open in the Cedars-Sinai Medical Center pipeline

70 recruiting of 339 indexed (21% open); 180 completed (53%).

Phase mix: 42 late (III/IV) vs 83 early (I/II) (early-phase heavy).

Top condition: Bladder Cancer (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Cedars-Sinai Medical Center: open-pipeline peers nationwide

Peers matched on 339 registered trials and 21% open enrollment, not the therapeutic-area sidebar.

Cedars-Sinai Medical Center sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 5%10%15%20%25% Total trials Recruiting share Cedars-Sinai Medical CenterNational Institutes of Health Clinical Center (CC)Ohio State University Comprehensive Cancer CenterChildren's Oncology GroupNational Institute of Mental Health (NIMH)University of Colorado, DenverCraig HospitalW.L.Gore & AssociatesGeorgia Institute of Technology
Cedars-Sinai Medical Center sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cedars-Sinai Medical Center sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 339 trials (± recruiting share)

Sponsors near 21% open enrollment (± trial volume)

What to do with this Cedars-Sinai Medical Center page

339 registered trials is a research-attention snapshot, not an endorsement of Cedars-Sinai Medical Center or any single study.

  • 70 of Cedars-Sinai Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Bladder Cancer is the condition Cedars-Sinai Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bladder Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cedars-Sinai Medical Center pipeline card: 339 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.